Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Neuropathic Pain

  • Neurologic Manifestations of Systemic Disease (A Pruitt, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Neuropathic pain is notoriously variable in its severity and impact on patients, as well as in its response to treatment. Certain therapies for neuropathic pain have better evidence for their use; however, it is apparent that although some therapies provide relief for only a minority of patients, the relief may be significant. Without a trial of therapy, there is no way to know if that relief is achievable. Our treatment experiences have shown that occasionally unexpected benefit is obtained through a thorough investigation of all options, even in the setting of failure of those with the most compelling evidence or indication. Chronic neuropathic pain is generally best treated with regularly dosed medications, balancing efficacy and tolerability. Evidence supports first-line trials of anticonvulsants, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors, alone or in certain combinations. While opioid medications, particularly methadone, can be effective in treating neuropathic pain, they are best used only in refractory cases and by experienced clinicians, due to concerns for both short- and long-term safety. Some therapies have a long history of successful use for certain syndromes (e.g., carbamazepine for trigeminal neuralgia pain), but these should not be considered to the exclusion of other more recent, less-supported therapies (e.g., botulinum toxin A for the same), particularly in refractory cases. We find the principles of palliative care highly applicable in the treatment of chronic neuropathic pain, including managing expectations, mutually agreed-upon meaningful outcomes, and a carefully cultivated therapeutic relationship.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Treede RD et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.

    Article  CAS  PubMed  Google Scholar 

  2. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2010;3:CD007076.

    Google Scholar 

  3. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938.

    PubMed  Google Scholar 

  4. Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Sym Manage. 2003;25(5 Suppl):S12–7.

    Article  Google Scholar 

  5. Backonja M-M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16(2 Suppl):S67–72.

    Article  CAS  PubMed  Google Scholar 

  6. Gilron I, Bailey JM, Tu D, Holden RH, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2009;374(9697):1252–61.

    Article  CAS  PubMed  Google Scholar 

  7. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013–28. Guidelines helpful in diagnosis and treatment of trigeminal neuralgia.

    Article  CAS  PubMed  Google Scholar 

  8. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2013;3:CD007963.

    PubMed  Google Scholar 

  9. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2014;4:CD005451.

    PubMed  Google Scholar 

  10. Finnerup NB et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73. Extensive review with references of anti-neuropathic agents.

    Article  CAS  PubMed  Google Scholar 

  11. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976–8.

    Article  CAS  PubMed  Google Scholar 

  12. Liamis G, Milionis H, Esilaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–53.

    Article  CAS  PubMed  Google Scholar 

  13. Gomez-Arguelles JM, Dorado R, Sepulveda JM, Herrera A, Arrojo FG, Aragon E, et al. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. J Clin Neurosci. 2008;15(5):516–9.

    Article  CAS  PubMed  Google Scholar 

  14. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25(5 Suppl):S31–5.

    Article  CAS  PubMed  Google Scholar 

  15. Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka E. Neuronal and immunological basis of action of antidepressants in chronic pain—clinical and experimental studies. Pharmacol Rep. 2013;65(6):1611–21.

    Article  CAS  PubMed  Google Scholar 

  16. Baltenberger EP, Buterbaugh WM, Martin BS. Review of antidepressants in the treatment of neuropathic pain. Ment Health Clinician. 2015;5(3):123–33.

    Article  Google Scholar 

  17. Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy. 2001;21(9):1070–81.

    Article  CAS  PubMed  Google Scholar 

  18. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454.

    PubMed  Google Scholar 

  19. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;12:CD008242.

    PubMed  Google Scholar 

  20. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain, or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.

    PubMed  Google Scholar 

  21. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain. Diabetes Care. 2012;35(12):2451–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain (protocol). Cochrane Database Syst Rev. 2014;4:CD011091.

    Google Scholar 

  23. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57(5):503–9.

    Article  CAS  PubMed  Google Scholar 

  24. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol. 1996;16(3 Suppl 2):21S–6S.

    Article  CAS  PubMed  Google Scholar 

  25. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromusc Dis. 2001;3(2):53–62.

    Article  CAS  Google Scholar 

  26. Vranken JH. Elucidation of pathophysiology and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2012;12(4):304–14.

    Article  CAS  PubMed  Google Scholar 

  27. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.

    PubMed  Google Scholar 

  28. Moulin DE et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manage. 2014;19(6):328–35.

    Google Scholar 

  29. Franklin GM. Opioids for chronic noncancer pain: a position paper from the American Academy of Neurology. Neurology. 2014;83(14):1277–84. Extensive review with references of anti-neuropathic agents.

    Article  CAS  PubMed  Google Scholar 

  30. Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. Can J Nerol Sci. 2005;32(3):340–3.

    Article  CAS  Google Scholar 

  31. Altier N, Dion D, Boulanger A, Choiniere M. Management of chronic neuropathic pain with methadone: a review of 13 cases. Clin J Pain. 2005;21(4):364–9.

    Article  PubMed  Google Scholar 

  32. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled cross-over trial. Pall Med. 2003;17(7):576–87.

    Article  Google Scholar 

  33. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manage. 2003;8(3):149–54.

    Google Scholar 

  34. Texeira MJ et al. Methadone in post-herpetic neuralgia: a pilot proof-of-concept study. Clinics. 2013;68(7):1057–60.

    Article  Google Scholar 

  35. Chou R, Weimer M, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence Clinical Practice Guideline. J Pain. 2014;15(4):338–65.

    Article  CAS  PubMed  Google Scholar 

  36. Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156 Suppl 1:S104–14. Extensive review with references of anti-neuropathic agents.

    Article  PubMed  Google Scholar 

  37. Finnerup NB, Attal N. Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy—author’s reply. Lancet Neurol. 2015;14(7):685–6.

    Article  PubMed  Google Scholar 

  38. Wolff M, Schnöbel-Ehehalt R, Mühling J, Weigand MA, Olschewski A. Mechanisms of lidocaine’s action on subtypes of spinal dorsal neurons subject to the diverse roles of Na+ and K+ channels in action potential generation. Anesth Analg. 2014;119(2):463–70.

    Article  CAS  PubMed  Google Scholar 

  39. Werdehausen R et al. Lidocaine metabolites inhibit glycine transporter 1. A novel mechanism for the analgesic action of systemic lidocaine? Anesthesiology. 2012;116(1):147–58.

    Article  CAS  PubMed  Google Scholar 

  40. Brinkrolf P, Hahnenkamp K. Systemic lidocaine in surgical procedures: effects beyond sodium channel blockade. Curr Opin Anesthesiol. 2014;27(4):420–5.

    Article  CAS  Google Scholar 

  41. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005;4:CD003345.

    PubMed  Google Scholar 

  42. Attal N, Gaudé V, Brasseur L, Dupuy M, Guirimand F, Parker F, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54(3):564–74.

    Article  CAS  PubMed  Google Scholar 

  43. Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diab Comp. 2006;20(1):34–9.

    Article  Google Scholar 

  44. Finnerup NB et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology. 2005;102(5):1023–30.

    Article  CAS  PubMed  Google Scholar 

  45. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 1991;41(7):1024–8.

    Article  CAS  PubMed  Google Scholar 

  46. Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain. 2006;22(3):266–71.

    Article  PubMed  Google Scholar 

  47. Schwartzman RJ, Patel M, Grothusen JR, Alexander GM. Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome. Pain Medicine. 2009;10(2):401–12.

    Article  PubMed  Google Scholar 

  48. Wu CL. Analgesic effects of intravenous lidocaine and morphine on post-amputation pain: a randomized double-blind, active placebo-controlled, crossover trial. Anesthesiology. 2002;96(4):841–8.

    Article  CAS  PubMed  Google Scholar 

  49. Raphael JH, Southall JL, Treharne GJ, Kitas GD. Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. BMC Musculoskelet Disord. 2002;3:21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Ferrini R. Clinical Practice Guideline: the use of lidocaine infusion in inpatient and home care settings. AAHPM Bulletin. 2001;1(2):1–15.

    Google Scholar 

  51. Sleigh J, Harvey M, Voss L, Denny B. Ketamine—more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4(2–3):76–81.

    Article  Google Scholar 

  52. Blonk MI et al. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2010;14(5):466–72.

    Article  CAS  PubMed  Google Scholar 

  53. Eichenberger U et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg. 2008;106(4):1265–73.

    Article  CAS  PubMed  Google Scholar 

  54. Collins S et al. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Medicine. 2010;11:1726–42.

    Article  PubMed  Google Scholar 

  55. Birklein F, O’Neill D, Schlereth T. Complex regional pain syndrome: an optimistic perspective. Neurology. 2015;84(1):89–96.

    Article  PubMed  Google Scholar 

  56. Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patient with complex regional pain syndrome. CNS Drugs. 2012;26(3):215–28.

    Article  CAS  PubMed  Google Scholar 

  57. Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg. 2014;119(1):170–8.

    Article  CAS  PubMed  Google Scholar 

  58. Prommer EE. Ketamine for pain: an update of uses in palliative care. J of Pall Med. 2012;15(4):474–83.

    Article  Google Scholar 

  59. Vo T, Rice ASC, Dworkin R. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain. 2009;143(3):169–71.

    Article  PubMed  Google Scholar 

  60. Moore RA, Chi CC, Wiffen PJ, Derry S. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain (protocol). Cochrane Database Syst Rev. 2013;12:CD010902.

    Google Scholar 

  61. Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Medicine. 2011;9:38.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Trelle S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Romundstad L. Glucocorticoids for acute and persistent postoperative neuropathic pain what is the evidence? Anesthesiology. 2007;107(3):371–3.

    Article  PubMed  Google Scholar 

  64. Gray P. Acute neuropathic pain: diagnosis and treatment. Curr Opin Anaesthesiol. 2008;21(5):590–5.

    Article  PubMed  Google Scholar 

  65. Armon C, Argoff CE, Samuels J, Backonja MM. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain. Neurology. 2007;68(10):723–9.

    Article  CAS  PubMed  Google Scholar 

  66. Dworkin RH et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–51.

    Article  CAS  PubMed  Google Scholar 

  67. O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22–32.

    Article  PubMed  Google Scholar 

  68. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111–7.

    Article  CAS  PubMed  Google Scholar 

  69. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;2:CD007393.

    PubMed  Google Scholar 

  71. Dobson JL, McMillan L, Li L. Benefits of exercise intervention in reducing neuropathic pain. Front Cell Neurosci. 2014;8:102.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Akyuz G, Kenis O. Physical therapy modalities and rehabilitation techniques in the management of neuropathic pain. Am J Phys Med Rehabil. 2014;93(3):253–9.

    Article  PubMed  Google Scholar 

  73. Allen N, Moloney N, van Vilet V, Canning CG. The rationale for exercise in the management of pain in Parkinson’s disease. J Parkinsons Dis. 2015;5:229–39.

    Article  CAS  PubMed  Google Scholar 

  74. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216–23.

    Article  PubMed  Google Scholar 

  75. Dixit S, Maiya AG, Shastry BA. Effect of aerobic exercise on peripheral nerve functions of population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, parallel group randomized controlled trial. J Diabetes Complications. 2014;28(3):332–9.

    Article  PubMed  Google Scholar 

  76. Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012;26(5):424–9.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain: a double blind placebo controlled study. Ann Neurol. 2008;64(3):274–83.

    Article  PubMed  Google Scholar 

  78. Apalla Z, Sotirou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–64.

    Article  PubMed  Google Scholar 

  79. Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443–50.

    Article  PubMed  Google Scholar 

  80. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–8.

    Article  CAS  PubMed  Google Scholar 

  81. Koppel B, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Neurology. 2014;82(17):1556–63.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Turk DC, Audette J, Levy RM, Mackey SC, Stanos S. Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain. Mayo Clin Proc. 2010;85(3 Suppl):S42–50.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Moseley GL. Using visual illusion to reduce at-level neuropathic pain in paraplegia. Pain. 2007;130(3):294–8.

    Article  PubMed  Google Scholar 

  84. Lee MM, Cho HY, Song CH. The mirror therapy program enhances upper-limb motor recovery and motor function in acute stroke patients. Am J Phys Med Rehabil. 2012;91(8):689–700.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Matthew T. Mendlik MD, PhD

  2. Department of Pharmacy, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Tanya J. Uritsky PharmD, BCPS

  3. Palliative Care Service, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Matthew T. Mendlik MD, PhD & Tanya J. Uritsky PharmD, BCPS

Authors
  1. Matthew T. Mendlik MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanya J. Uritsky PharmD, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew T. Mendlik MD, PhD.

Ethics declarations

Conflict of Interest

Matthew T. Mendlik and Tanya J. Uritsky declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neurologic Manifestations of Systemic Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mendlik, M.T., Uritsky, T.J. Treatment of Neuropathic Pain. Curr Treat Options Neurol 17, 50 (2015). https://doi.org/10.1007/s11940-015-0381-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-015-0381-2

Keywords

Search

Navigation